BARDA and JPEO-CBRND partner with Grand River Aseptic Manufacturing to expand domestic fill-finish capacity for COVID-19 countermeasures under Operation Warp Speed
BARDA and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) are partnering with Grand River Aseptic Manufacturing, Inc. (“GRAM”) to expand the capacity and ensure access for filling and finishing vaccines or therapeutics in the United States.
Filling and finishing vials are the last two steps in the manufacturing process for vaccines and drugs. With this award to GRAM, the U.S. government helps ensure that the country will have enough domestic capacity to complete these critical final steps to make vaccines or therapeutics available to the American people. As part of this agreement, the federal government will reserve fill-finish capacity on a commercial filling line for use by federal partners that are developing COVID-19 vaccines or therapeutic treatments.
This partnership provides the support needed for GRAM to complete fill-finish activities for U.S.-based vaccines or therapeutic products. This capacity not only supports the COVID-19 pandemic response but also increases U.S. preparedness for future public health emergencies. As a U.S.-based contract development and manufacturing organization (CDMO), GRAM is well-equipped to support the pharmaceutical supply chain through this challenging time by offering state-of-the-art technology delivering the highest quality products.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
About Grand River Aseptic Manufacturing, Inc. (“GRAM”):
The following information is provided by company and does not indicate endorsement by the federal government of the company or its products.
Grand River Aseptic Manufacturing, Inc. (“GRAM”), a parenteral contract development and manufacturing organization, delivers customized solutions to meet clients’ fill and finish needs from development through commercialization. With capabilities for biologics as well as controlled substances, GRAM’s expert project managers and modern facilities support pharmaceutical development and cGMP manufacturing, analytical testing, and regulatory filing.